Table 1.
Demographics and baseline characteristics.
| Variable | n (%) | |
|---|---|---|
| Gender | Male | 58 (73.4) |
| Female | 21 (26.6) | |
| Race | White | 61 (77.2) |
| Black | 17 (21.5) | |
| Asian | 1 (1.3) | |
| ECOG PS | 0-1 | 58 (75.3) |
| 2+ | 19 (24.7) | |
| Missing | 2 | |
| ccRCC | Yes | 55 (74.3) |
| No | 19 (25.7) | |
| Missing | 5 | |
| Anti-PD-1 Monotherapy | Yes | 47 (59.5) |
| No | 32 (40.5) | |
| Prior Lines of Therapy | 0 | 28 (35.4) |
| 1 | 40 (50.6) | |
| 2 | 7 (8.9) | |
| 3+ | 4 (5.1) | |
| Number of distant metastatic sites | 1 | 12 (15.2) |
| 2 | 27 (34.2) | |
| 3+ | 40 (50.6) | |
| IMDC Risk Groups | Favorable | 12 (15.2) |
| Intermediate | 43 (54.4) | |
| Poor | 24 (30.4) | |
| Baseline BMI (Median: 26.2) | ≤25 | 29 (37.2) |
| >25 | 49 (62.8) | |
| Missing | 1 | |
| Median (Optimal Cut-Off) Muscle and Adipose Variables | SMI | M: 44.0, F: 39.2 |
| Attenuated SM Mean | M: 35.1, F: 34.4 | |
| SFI | M: 51.4, F: 69.8 | |
| IFI | M: 4.4, F: 7.8 | |
| VFI | M: 35.2, F: 37.4 | |
| TFI | M: 98.7, F: 94.3 | |
| Median Age: 61.0 years | ||
ECOG PS, Eastern cooperative oncology group performance status; ccRCC, clear cell renal cell carcinoma; BMI, body mass index; SMI, skeletal muscle index; SM, skeletal muscle; SFI, subcutaneous fat index; IFI, inter-muscular fat index; VFI, visceral fat index.